Aeterna Zentaris Inc. (NASDAQ:AEZS) has been assigned a consensus broker rating score of 1.25 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a buy rating and three have assigned a strong buy rating to the company.

Brokerages have set a 12-month consensus price target of $11.00 for the company and are predicting that the company will post ($0.74) earnings per share for the current quarter, according to Zacks. Zacks has also given Aeterna Zentaris an industry rank of 92 out of 265 based on the ratings given to related companies.

A number of research analysts have commented on the company. Maxim Group restated a “buy” rating and set a $11.00 price objective on shares of Aeterna Zentaris in a research note on Wednesday, June 15th. Canaccord Genuity reaffirmed a “buy” rating and set a $9.00 target price on shares of Aeterna Zentaris in a research report on Tuesday, August 23rd. HC Wainwright reaffirmed a “buy” rating on shares of Aeterna Zentaris in a research report on Thursday, August 11th. Finally, Zacks Investment Research raised Aeterna Zentaris from a “hold” rating to a “buy” rating and set a $4.00 target price on the stock in a research report on Monday, August 15th.

A hedge fund recently raised its stake in Aeterna Zentaris stock. Renaissance Technologies LLC increased its position in shares of Aeterna Zentaris Inc. (NASDAQ:AEZS) by 5.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 516,833 shares of the biopharmaceutical company’s stock after buying an additional 29,000 shares during the period. Renaissance Technologies LLC owned about 8.17% of Aeterna Zentaris worth $1,716,000 as of its most recent SEC filing. 8.28% of the stock is currently owned by institutional investors and hedge funds.

Aeterna Zentaris (NASDAQ:AEZS) opened at 3.35 on Wednesday. Aeterna Zentaris has a 12 month low of $2.60 and a 12 month high of $15.70. The stock’s market capitalization is $33.30 million. The company’s 50-day moving average price is $3.56 and its 200 day moving average price is $3.56.

Aeterna Zentaris (NASDAQ:AEZS) last issued its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.11. Aeterna Zentaris had a negative return on equity of 241.78% and a negative net margin of 5,871.45%. On average, analysts forecast that Aeterna Zentaris will post ($2.61) earnings per share for the current fiscal year.

About Aeterna Zentaris

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

5 Day Chart for NASDAQ:AEZS

Get a free copy of the Zacks research report on Aeterna Zentaris (AEZS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aeterna Zentaris Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.